title: Immunological correlates of cure in the first American cutaneous leishmaniasis patient treated by immunotherapy in Argentina. A case report.
abstract: A patient with localized cutaneous leishmaniasis due to Leishmania (Leishmania) amazonensis infection was treated with an antigen containing heat-killed L. (L.) amazonensis promastigotes plus BCG. Expression of T-cell differentiation, memory and senescence receptors markers were analyzed on T cell subpopulations, in order to establish the correlation between the percentages of expression of these receptors and his clinical status, at different stages of his follow up. The following case reports on the achievement of a successful clinical outcome with complete resolution after receiving immunotherapy. A thorough clinical and immunological follow up supporting the healing process of this patient's lesion is presented in detail.
authors.affiliation: Instituto de Patología Experimental, Facultad de Ciencias de la Salud, Universidad Nacional de Salta, Salta, Argentina. mfbustos@unsa.edu.ar
authors.forename: María Fernanda
authors.initials: MF
authors.lastname: García Bustos
authors.forename: Alejandra Beatriz
authors.initials: AB
authors.lastname: Barrio
authors.forename: Cecilia Maria
authors.initials: CM
authors.lastname: Parodi Ramoneda
authors.forename: Federico
authors.initials: F
authors.lastname: Ramos
authors.forename: María Celia
authors.initials: MC
authors.lastname: Mora
authors.forename: Jacinto
authors.initials: J
authors.lastname: Convit
authors.forename: Miguel Angel
authors.initials: MA
authors.lastname: Basombrío
mesh_terms: D000328:Adult; D000953:Antigens, Protozoan / Q000008:administration & dosage / Q000276:immunology / Q000627:therapeutic use*; D001118:Argentina / Q000453:epidemiology; D001500:BCG Vaccine / Q000008:administration & dosage / Q000627:therapeutic use*; D005398:Fisheries; D006801:Humans; D007111:Immunity, Cellular; D007156:Immunologic Memory; D016233:Immunotherapy, Active; D007271:Injections, Intradermal; D007871:Leg Ulcer / Q000209:etiology / Q000469:parasitology; D007894:Leishmania mexicana / Q000254:growth & development / Q000276:immunology*; D016773:Leishmaniasis, Cutaneous / Q000453:epidemiology / Q000276:immunology / Q000469:parasitology / Q000628:therapy*; D008297:Male; D009784:Occupational Diseases / Q000276:immunology / Q000469:parasitology / Q000628:therapy*; D016052:Protozoan Vaccines / Q000008:administration & dosage / Q000276:immunology / Q000627:therapeutic use*; D016176:T-Lymphocyte Subsets / Q000276:immunology; D015164:Vaccines, Inactivated
chemical_list: D000953:Antigens, Protozoan; D001500:BCG Vaccine; D016052:Protozoan Vaccines; D015164:Vaccines, Inactivated